In the training cohort, AML patients with high TOX2, TOX3, and TOX4 expression had shorter survival time and more inferior OS (3-year OS: 0% vs. 37%, P = 0.036; 3-year OS: 4% vs. 61%, P < 0.001; 3-year OS: 0% vs. 32%, P = 0.010, Figures 3B–D). The gene discussed is TOX2; the disease is acute myeloid leukemia.